ADTAB 3 Tablets 450 mg Dogs 11-22 kg

Veterinary antiparasitic in chewable tablets based on lotilaner, against fleas and ticks in dogs from 11 to 22 kg. Pack of 3 tablets.
In stock, ready to ship
105723086
€26.44
Tax included

  • Express delivery: in 24/48 hours
    Standard in 3-5 working days
  • Shipping
    Standard €6.50, express €9.00
    Sardinia, Venice and minor islands: €20.00
  • Returns within 14 days
    Right of withdrawal guaranteed
  • Secure payments
    Visa, Mastercard, American Express, PayPal, PayPal in 3 rate, Google Pay, Klarna, Bonifico

Need help? Contact us

Description

Name

ADTAB CHEWABLE TABLETS FOR DOGS

Pharmacotherapeutic Category

Ectoparasiticides for systemic use.

Active Substances

Active substance: chewable tablet. AdTab chewable tablets for dogs (1.3-2.5 kg). Lotilaner: 56.25 mg. AdTab chewable tablets for dogs (>2.5-5.5 kg). Lotilaner: 112.5 mg. AdTab chewable tablets for dogs (>5.5-11 kg). Lotilaner: 225 mg. AdTab chewable tablets for dogs (>11-22 kg). Lotilaner: 450 mg. AdTab chewable tablets for dogs (>22 -45 kg). Lotilaner: 900 mg.

Excipients

Powdered cellulose, lactose monohydrate, silicified microcrystalline cellulose, dried meat flavour, crospovidone, povidone K30, sodium lauryl sulfate, colloidal anhydrous silica, magnesium stearate.

Indications

For the treatment of flea and tick infestations in dogs. This veterinary medicinal product provides immediate and persistent flea-killing (Ctenocephalides felis and C. canis) and tick-killing (Rhipicephalus sanguineus, Ixodes ricinus, I. hexagonus and Dermacentor reticulatus) activity for 1 month. Fleas and ticks must attach to the host and start feeding in order to be exposed to the active substance.

Contraindications/Adverse Effects

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Safety in the Target Species

No adverse reactions were observed after oral administration to puppies aged 8 to 9 weeks with a body weight of 1.3-3.6 kg, treated with overdoses of up to 5 times the maximum recommended dose (43 mg, 129 mg and 215 mg of lotilaner/kg body weight) on eight occasions at monthly intervals.

Dosage

For oral use. The veterinary medicinal product should be administered according to the following list to ensure a lotilaner dose of 20 to 43 mg/kg body weight. Dog body weight: 1.3-2.5 kg. Strength and number of tablets to administer. AdTab 56 mg: 1. Dog body weight: >2.5- 5.5 kg. Strength and number of tablets to administer. AdTab 112 mg: 1. Dog body weight: >5.5-11.0 kg. Strength and number of tablets to administer. AdTab 225 mg: 1. Dog body weight: >11.0-22.0 kg. Strength and number of tablets to administer. AdTab 450 mg: 1. Dog body weight: >22.0-45.0 kg. Strength and number of tablets to administer. AdTab 900 mg: 1. Dog body weight: >45 kg. Strength and number of tablets to administer: appropriate combination of tablets. For dogs weighing more than 45 kg, use an appropriate combination of the available strengths to achieve the recommended dose of 20-43 mg/kg. Underdosing may result in ineffectiveness and may favour the development of resistance. To ensure correct dosing, body weight should be determined as accurately as possible. AdTab is a palatable flavoured chewable tablet. Administer the chewable tablet with food or after meals. For optimal control of flea and tick infestation, the product should be administered at monthly intervals during the flea and/or tick season, based on the local epidemiological situation.

Storage

This veterinary medicinal product does not require any special storage conditions. Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Warnings

Parasites need to start feeding on the host to become exposed to lotilaner; therefore the risk of transmission of parasite-borne diseases cannot be completely excluded. The possibility that other animals in the same household may be a source of flea reinfestation should be considered, and these should be treated as necessary with an appropriate product. Fleas, at every stage of their development, can infest the dog's bedding and normal resting areas such as carpets and soft furnishings. In case of massive flea infestation, and at the start of control measures, these areas should be treated with a suitable environmental product and then cleaned regularly. Special precautions for safe use in the target species: all efficacy and safety data have been obtained from dogs and puppies aged 8 weeks or older and weighing 1.3 kg or more. In the absence of available data, a veterinary surgeon should be consulted before treating puppies under 8 weeks of age or weighing less than 1.3 kg. Special precautions to be taken by the person administering the veterinary medicinal product to animals: wash hands after handling the product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the doctor. Special precautions for the protection of the environment: not applicable. No adverse reactions were observed after oral administration to puppies aged 8 to 9 weeks with a body weight of 1.3-3.6 kg, treated with overdoses of up to 5 times the maximum recommended dose (43 mg, 129 mg and 215 mg of lotilaner/kg body weight) on eight occasions at monthly intervals. Incompatibilities: not applicable.

Withdrawal Periods

Not applicable.

Target Species

Dog.

Interactions

None known. During clinical field studies, no interactions were observed between lotilaner and routinely used veterinary medicinal products.

Diagnosis and Prescription

Veterinary medicinal product not subject to prescription.

Adverse Effects

Target species: Dog. Very rare (<1 animal / 10,000 animals treated, including isolated reports): , anorexia ^1,2, lethargy ^2, ataxia ^3, convulsions ^3, tremor ^3. ^1 Mild and transient. ^2 Usually resolve without treatment. ^3 Transient in most cases. Reporting adverse events is important as it allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinary surgeon, to the marketing authorisation holder or to the national competent authority via the national reporting system. See also the "Contact details" section of the package leaflet.

Pregnancy and Lactation

The safety of the veterinary medicinal product during pregnancy, lactation or in breeding dogs has not been established. Pregnancy and lactation: laboratory studies in rats have not produced any evidence of teratogenic effects or adverse effects on the reproductive capacity of males and females. Consult a veterinary surgeon before use during pregnancy and lactation. Fertility: consult a veterinary surgeon before treating breeding dogs.

Product Details

Format
CHEWABLE TABLETS
82 Items
5420036974307

10 other products in the same category:

Product added to wishlist
Product added to compare.